Chief Financial Officer

Prior to joining Aeovian in February 2024, Micah Zajic served as LEXEO Therapeutics’ Chief Financial Officer and later transitioned as LEXEO’s Chief Business Officer where he focused on the evaluation and execution of external partnerships, license agreements and acquisitions. 

​

Prior to LEXEO, Mr. Zajic served as Chief Business Officer and later Chief Financial Officer at SQZ Therapeutics where he led the business development, finance, investor relations and operations functions. He also led SQZ’s strategic collaboration with Roche, in addition taking the company public and Raising $130M+ in capital.

​

Prior to SQZ, Mr. Zajic held Corporate Development and Strategy roles at MeiraGTx and Alexion Pharmaceuticals, respectively, where he focused on the evaluation and execution of external partnerships, license agreements and acquisitions. Earlier in his career, he held various roles at Morgan Stanley where he spent over 10 years in the Global Capital Markets and Healthcare Investment Banking Groups raising capital and executing strategic transactions for companies across the healthcare industry.

​

 Mr. Zajic received his BA in Economics from Georgetown University.